NCT00510965View on ClinicalTrials.gov

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Choroidal Neovascularization
Interventions
DRUG

Intravitreal injection ranibizumab

Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year

Trial Locations (1)

53127

University of Bonn, Bonn

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital, Bonn

OTHER

NCT00510965 - Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) | Biotech Hunter | Biotech Hunter